CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...
Phase 2, Phase 3
Berlin, Germany and 217 other locations
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
Berlin, Germany and 199 other locations
(NACT) is standard of care in all node-positive and in node-negative patients with a tumour size \>5 mm according to current National Compre...
Phase 2
Berlin, Brandenburg, Germany and 32 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Berlin, Germany and 516 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Berlin, Germany and 505 other locations
vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...
Phase 3
Berlin, Germany and 192 other locations
to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received n...
Phase 3
Berlin, Germany and 209 other locations
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It wi ...
Phase 1
Berlin, Germany and 40 other locations
works to treat solid tumor cancers.* Part D will find out if and how much Felmetatug Vedotin can be given with pembrolizumab.* Par ...
Phase 1
Berlin, Germany and 30 other locations
Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer...
Phase 3
Berlin, Germany and 162 other locations
Clinical trials
Research sites
Resources
Legal